State Street Corp Oncocyte Corp Transaction History

State Street Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$0.76 - $15.98 $34,428 - $723,894	-45,300 Reduced 13.85%	281,845 $206,000
Q2 2022 Aug 15, 2022	SELL	$0.86 - $1.53 $886,116 - $1.58 Million	-1,030,368 Reduced 75.9%	327,145 $294,000
Q1 2022 May 16, 2022	SELL	$1.15 - $2.25 $32,140 - $62,883	-27,948 Reduced 2.02%	1,357,513 $2.02 Million
Q4 2021 Feb 14, 2022	SELL	$2.04 - $3.59 $36,930 - $64,989	-18,103 Reduced 1.29%	1,385,461 $3.01 Million
Q3 2021 Nov 15, 2021	BUY	$3.53 - $5.89 $495,488 - $826,749	140,365 Added 11.11%	1,403,564 $5 Million
Q2 2021 Aug 16, 2021	BUY	$3.77 - $6.0 $579,988 - $923,058	153,843 Added 13.87%	1,263,199 $7.25 Million
Q1 2021 May 17, 2021	BUY	$2.39 - $6.5 $422,733 - $1.15 Million	176,876 Added 18.97%	1,109,356 $5.76 Million
Q4 2020 Feb 16, 2021	BUY	$1.38 - $2.63 $342,023 - $651,827	247,843 Added 36.2%	932,480 $2.23 Million
Q3 2020 Nov 10, 2020	BUY	$1.2 - $1.89 $71,982 - $113,371	59,985 Added 9.6%	684,637 $952,000
Q2 2020 Aug 14, 2020	BUY	$1.91 - $3.45 $373,966 - $675,489	195,794 Added 45.65%	624,652 $1.19 Million
Q1 2020 May 11, 2020	BUY	$1.76 - $3.02 $754,790 - $1.3 Million	428,858 New	428,858 $1.05 Million

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $294M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.